GlassScriptPhysician profile
Perry Kent Bohanon
NPI 1467437178
$8,532.91
in general payments reported to CMS, 2019-2025
19 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,261 · 2022: $1,406 · 2023: $2,777 · 2024: $1,748 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,820 · Education: $46.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,819.82 |
| Education | $46.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,402.90 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,063.97 | 2021-2023 | Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $491.02 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $482.65 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $474.00 | 2021-2024 | Spravato |
| Axsome Therapeutics, INC. | $439.97 | 2023-2024 | Auvelity |
| Acadia Pharmaceuticals INC | $409.20 | 2023 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $280.96 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.65 | 2021-2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $89.32 | 2023 | Quviviq |
| Neurocrine Biosciences, INC. | $74.15 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $59.60 | 2021-2024 | Abilify Maintena |
| Alfasigma USA, INC. | $44.87 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $43.34 | 2025 | Fanapt, Hetlioz |
| Noven Therapeutics, LLC | $27.34 | 2021-2025 | Xelstrym |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $22.29 | 2022 | |
| Novo Nordisk INC | $15.94 | 2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $12.40 | 2021 | |
| Corium, LLC | $6.34 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perry Bohanon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.